| Original Article |
Question: What is the association between irritable bowel syndrome (IBS) and long-term risk of overall, site-specific cancer and cancer-specific mortality in the general population?
Design/Method: A large-scale prospective cohort study was done based on the UK bio-bank data between 2006 and 2010. Participants free of inflammatory bowel disease, celiac disease, and any cancer at baseline from the UK Biobank were included, with patients with IBS as the exposure group and non-IBS patients as the reference group. The primary outcome was the incidence of overall cancer and cancer-specific mortality. Secondary outcomes included site-specific cancers and types of digestive cancers. The Cox proportional hazard model was used to investigate the associated risk of incident malignancies and related mortality
Setting: The United Kingdom
Patient/Study community: Patients with a previous cancer diagnosis, IBS, and celiac disease ranging from age 37 to 73 years
Results: Totally, IBS does not lead to increased risk of overall cancer vs non-IBS individuals. Conversely, patients with IBS have a lower risk of incident CRC and cancer-specific mortality
Commentary:
| Persons with IBS have a lower risk of developing CRC incidentally and dying from cancer. The results of this study, in this case, reassure IBS sufferers that their condition is unlikely to progress to CRC in the future and won’t limit their life expectancy as a result of cancer. This should be taken into account by IBS patients as well as professionals to improve the management of IBS disorders and conserve healthcare expenditures |
Citation: Shanshan Wu, Changzheng Yuan, Si Liu, and et all. Irritable bowel syndrome and long-term risk of cancer: A prospective cohort study among 0.5 million adults in UK biobank. The American Journal of Gastroenterology. 2022; 117(5):785–793
DOI: 10.14309/ajg.0000000000001674
https://pubmed.ncbi.nlm.nih.gov/35130187/
Topics: IBS, Neoplasm, Digestive Cancers
